Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Vanguard Health Care ETF (VHT) is rated a hold due to high valuations and low profitability of top holdings despite strong ...

Lilly will seek review of decision which said drug's benefits don’t outweigh risk of potentially fatal bleeding in the brain ...

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...

Fearing potential tariffs from President Trump's announcement, some European drugmakers are increasing air shipments of ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...